Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Hematologic Malignancies
Filter by Topic
Leukemia
FDA Approves Split-Dosing Regimen for Daratumumab in Patients with Multiple Myeloma
FDA Approvals, News & Updates
,
Multiple Myeloma
,
Hematologic Malignancies
Web Exclusives
On February 12, 2019, the US Food and Drug Administration (FDA) granted approval for daratumumab (Darzalex; Janssen), a CD38-directed antibody, to be given in a split-dosing regimen to patients with multiple myeloma (MM). Darzalex is the first and only CD38-directed antibody to receive regulatory approval for the treatment of patients with MM and is the first to be approved for the split-dosing regimen. This new regimen gives patients and healthcare providers the option to split the first dose of Darzalex over the course of 2 consecutive days, which has the benefit of shortening the duration of the first infusion.
Read Article
Maintenance Therapy with Ixazomib Significantly Prolongs Progression-Free Survival Following Autologous Stem-Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: Results from the TOURMALINE-MM3 Trial
Maintenance Therapy
,
Multiple Myeloma
,
Hematologic Malignancies
Web Exclusives
San Diego, CA—In patients with multiple myeloma (MM), the use of drug therapy as maintenance has been shown to prolong the length of time the disease is controlled. Specifically, use of maintenance therapy may affect overall survival, particularly when it is used after an autologous stem-cell transplant (ASCT).
Read Article
Mechanism of Pathway: Considerations of Cytogenetic and Molecular Mutation Status for Patients with Acute Myeloid Leukemia: A Deeper Look at the Role of Diagnostic and Ongoing Testing Across the Care Continuum
Hematologic Malignancies
,
Leukemia
Mechanism of Pathway: Considerations of Cytogenetic and Molecular Mutation Status for Patients with Acute Myeloid Leukemia: A Deeper Look at the Role of Diagnostic and Ongoing Testing Across the Care Continuum
Acute myeloid leukemia (AML) is a heterogeneous disease that is characterized by uncontrolled proliferation of undifferentiated myeloid progenitors. While these leukemic blasts accumulate in the bone marrow and peripheral blood, impairment of normal hematopoiesis may lead to a reduction in the number of differentiated myeloid cells (granulocytes, neutrophils, monocytes, erythrocytes, megakaryocytes). Associated symptoms and consequences include anemia, bleeding, and an increased risk for infection.
Read Article
Once-Weekly Carfilzomib for Patients with Relapsed or Refractory Multiple Myeloma Improves Progression-Free Survival
By
Walter Alexander
2018 EHA Congress Highlights
,
Multiple Myeloma
,
Hematologic Malignancies
Web Exclusives
Once-weekly carfilzomib (Kyprolis) therapy at a higher dose significantly improved progression-free survival (PFS) and reduced the risk of disease progression or death compared with twice-weekly carfilzomib in patients with relapsed or refractory multiple myeloma. The overall safety profile for both regimens in the randomized phase 3 ARROW clinical trial were similar, said co-lead investigator María-Victoria Mateos, MD, PhD, Director, Myeloma Unit, University Hospital Salamanca-IBSAL, Spain, at the 2018 European Hematology Association Congress.
Read Article
Pomalidomide Added to the Regimen in First Relapse Extends PFS in Multiple Myeloma
By
Wayne Kuznar
Clinical Trials
,
Multiple Myeloma
,
Hematologic Malignancies
,
Personalized Medicine
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Read Article
Nelarabine Therapy Up Front Boosts Survival in T-Cell Leukemia and Lymphoma
By
Phoebe Starr
Hematologic Malignancies
,
Leukemia
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Read Article
Next-Generation Sequencing Could Help Treatment Decisions in Acute Myeloid Leukemia
By
Chase Doyle
Leukemia
,
Hematologic Malignancies
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Read Article
Investigational CAR T-Cell Therapy, bb2121, Shows Durable Responses in Relapsed or Refractory Multiple Myeloma
By
Wayne Kuznar
Immunotherapy
,
Multiple Myeloma
,
Hematologic Malignancies
,
Personalized Medicine
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Read Article
Palliative Care Use Dismal Among Patients with Hematologic Malignancies
ASH 2017
,
Multiple Myeloma
,
Palliative Care
,
Hematologic Malignancies
,
ASH Highlights
Web Exclusives
Read Article
New Multiple Myeloma Guideline Assigns Preferred Regimens for Primary, Maintenance Therapy
By
Wayne Kuznar
Multiple Myeloma
,
NCCN Guidelines
,
Hematologic Malignancies
Web Exclusives
Orlando, FL—The 2018 National Comprehensive Cancer Network (NCCN) updated guideline on the management of multiple myeloma assigns preferred status to certain treatment regimens, and designates others as recommended or useful in certain circumstances.
Read Article
Page 5 of 11
1
2
3
4
5
6
7
8
9
10
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma